Wire Stories

ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody

BETHESDA, Md. & PANGYO, South Korea--(BUSINESS WIRE)--ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory…

5 years ago

Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Japan Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) - Q1 2022 Update" report…

5 years ago

Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Japan Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) - Q1 2022 Update" report…

5 years ago

ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody

BETHESDA, Md. & PANGYO, South Korea--(BUSINESS WIRE)--ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory…

5 years ago

ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody

BETHESDA, Md. & PANGYO, South Korea--(BUSINESS WIRE)--ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory…

5 years ago

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders

- Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology - HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals…

5 years ago

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders

- Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology - HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals…

5 years ago

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders

- Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology - HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals…

5 years ago

Asia Pacific Buy Now Pay Later Markets and Investment Opportunities Report 2022: BNPL Payments are Expected to Grow by 61.5% to Reach US$133,696.8 Million in 2022 – Forecast to 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Buy Now Pay Later Business and Investment Opportunities - 75+ KPIs on Buy Now Pay Later…

5 years ago

Asia Pacific Buy Now Pay Later Markets and Investment Opportunities Report 2022: BNPL Payments are Expected to Grow by 61.5% to Reach US$133,696.8 Million in 2022 – Forecast to 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Buy Now Pay Later Business and Investment Opportunities - 75+ KPIs on Buy Now Pay Later…

5 years ago
Show more Posts
Show previous Posts

Search